Kwality Pharmaceuticals Limited

KPL6

INE552U01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:19:01 2024-04-26 am EDT			5-day change	1st Jan Change
507 ^INR	+1.36%		+13.03%	+26.81%

Feb. 06	Kwality Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Kwality Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Kwality Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023

May 28, 2022 at 09:25 am EDT

Kwality Pharmaceuticals Limited provided earnings guidance for the fiscal year 2023. For the period, the company expects revenue to be in the range of INR 3,500 million and INR 4,000 million.

Latest news about Kwality Pharmaceuticals Limited

Kwality Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 06	CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 04	CI
Kwality Pharmaceuticals Limited Provides Update on Resumption of Operations At Amritsar	23-10-07	CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-27	CI
Kwality Pharmaceuticals Discloses Completion of EU GMP Inspection at Himachal Pradesh, India Unit	23-04-24	MT
Kwality Pharmaceuticals Limited Receives ANVISA Approval for Cephalosporin Plant (Unit -II)	23-03-30	CI
Kwality Pharmaceuticals Limited Announces Change in Directorate	23-03-18	CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Bulgarian Drug Agency to Conduct Audit on Kwality Pharmaceuticals' Plant in Himachal Pradesh, India	22-12-28	MT
Kwality Pharmaceuticals to Bring Oncology Injection in Brazil	22-12-21	MT
Kwality Pharmaceuticals to Market Oncology Injection in Brazil	22-12-15	MT
Kwality Pharmaceuticals Received ANVISA Approval For Oncology Injection	22-12-15	CI
Kwality Pharmaceuticals Receives ANVISA Approval For Oncology Injection	22-12-15	CI
Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director	22-11-19	CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
ICRA Assigns BBB Rating on Kwality Pharmaceuticals' Bank Loans; Outlook Stable	22-09-20	MT
Kwality Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Kwality Pharmaceuticals Gets In-Principle Approval to Migrate to BSE Main Board	22-06-03	MT
Kwality Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023	22-05-28	CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2021	21-10-22	CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2021	21-06-30	CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2020	20-11-13	CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2020	20-07-13	CI
Kwality Pharmaceuticals Limited Resumes Operations of its All the Units & Plants in India	20-04-22	CI

Chart Kwality Pharmaceuticals Limited

Duration

Period

More charts

Kwality Pharmaceuticals Limited is a manufacturer of finished pharmaceutical formulations in a dosage form. The Company is engaged in the business of manufacturers, buyers, and sellers of and dealers in all kinds of drug intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages, and other medical preparations. It manufactures exports pharmaceutical formulations in liquid orals, powder for oral suspension, tablets, capsules, sterile powder for injections, small volume injectables, ointments, external preparations, oral rehydration solutions (ORS), and others in various categories like beta lactam and non-beta lactam, hormones, cytotoxic (oncology) and effervescent. The Company specializes in handling customized business as per the requirements. The Company has about 48 different sections available at their production centers. The Company has registered its products in different countries of Europe, Africa, Asia, and others.

Sector

Pharmaceuticals

Calendar

2024-05-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KWALITY PHARMACEUTICALS LIMITED	+26.81%	63.08M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B